Premium
Barrett's esophagus: proton pump inhibitors and chemoprevention I
Author(s) -
Triadafilopoulos George,
Taddei Antonio,
Bechi Paolo,
Freschi Giancarlo,
Ringressi Maria Novella,
Degli'Innocenti Duccio Rossi,
Castiglione Francesca,
Masini Emmanuella,
Majewski Marek,
Wallner Grzegorz,
Sarosiek Jerzy,
Dillon John F.,
McCallum Richard C.,
Dvorak Katerina,
Goldman Aaron,
Woodland Philip,
Sifrim Daniel,
Richter Joel E.,
Vieth Michael,
Neumann Helmut,
Langner Cord,
Ishimura Norihisa,
Amano Yuji,
Felix Valter Nilton
Publication year - 2011
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2011.06047.x
Subject(s) - esophagus , gastroenterology , medicine , normalization (sociology) , secretion , pharmacology , chemistry , sociology , anthropology
The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5‐HT 4 agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.